Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events için istatistikler

Toplam ziyaret

views
Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events 0

Aylık toplam ziyaret

views
Haziran 2024 0
Temmuz 2024 0
Ağustos 2024 0
Eylül 2024 0
Ekim 2024 0
Kasım 2024 0
Aralık 2024 0